About Contact Us Careers
Sign In

Methicillin-resistant Staphylococcus Aureus Drugs Market - Top Companies and Manufacturers

  • Report ID: 5531
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Companies Dominating the Methicillin-resistant Staphylococcus Aureus Drugs Landscape

    • BD (Becton, Dickinson, and Company)
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Melinta Therapeutics LLC
    • Dr. Reddy’s Laboratories Ltd.
    • Cardinal Health
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Baxter
    • Crown Laboratories, Inc.
    • Atlantic Biologicals
    • Apollo Health & Beauty Care
Browse Key Market Insights with Data Illustration:

In the News

  • BD (Becton, Dickinson, and Company) which is a leading international medical technology company, announced receiving a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application. This imaging application leverages artificial intelligence (AI) to interpret bacterial growth and releases negative specimens with minimal human intervention.
  • Melinta Therapeutics (Melinta) is a commercial-stage company that develops novel treatments for acute and life-threatening illnesses. The company recently announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that treats acute bacterial skin and skin structure infections (ABSSSI) completely with a single 1,200 mg infusion that takes one hour. On March 12, 2021, the U.S. Food and Drug Administration approved KIMYRSA for the treatment of adult patients with ABSSSI brought on by susceptible isolates of specific Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).  

Author Credits:  Radhika Pawar


  • Report ID: 5531
  • Published Date: Nov 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of methicillin-resistant staphylococcus aureus drugs is evaluated at USD 4.39 billion.

The methicillin-resistant staphylococcus aureus drugs market size was over USD 4.24 billion in 2024 and is poised to exceed USD 7.33 billion by 2037, growing at over 4.3% CAGR during the forecast period i.e., between 2025-2037. The market growth is propelled by the surge in the geriatric population, rising adoption of AI in healthcare, and rise in product approval.

North America industry is anticipated to dominate majority revenue share of 40% by 2037, impelled by rising COVID-19 cases in the region.

The major players in the market include BD (Becton, Dickinson, and Company), Melinta Therapeutics LLC, Dr. Reddy’s Laboratories Ltd., Cardinal Health, Pfizer Inc., Merck & Co., Inc., Baxter, Crown Laboratories, Inc., Atlantic Biologicals, Apollo Health & Beauty Care
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample